AbCellera to Participate Virtually in the Truist Securities AI Symposium

AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

February 23, 2022 | Last Trade: US$4.00 0.20 5.13

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will participate in a panel during the Truist Securities AI Symposium – Biotech & Tools. The panel is titled, “Integrated Platforms for AI-based Drug Discovery,” and will take place virtually on Tuesday, March 1, 2022, at 8:20 a.m. Pacific Time.

A live audio webcast of the panel may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Source: AbCellera Biologics Inc.

Stock Quote

Last Trade:	US$4.00
Daily Change:	0.20 5.13
Daily Volume:	7,135,751
Market Cap:	US$1.180B

May 30, 2025 AbCellera Biologics Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 May 14, 2025 AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause May 12, 2025 AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit May 09, 2025 AbCellera Biologics Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting May 08, 2025 AbCellera Reports Q1 2025 Business Results LOAD MORE NEWS

Featured Stock

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE